Clinical Trials
CSO Jacob Thyssen tells Scrip that the monoclonal antibody which blocks the IL-22RA1 receptor subunit is a very safe and effective option to treat the chronic inflammatory skin disease.
With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.
The company announced positive Phase III data for the drug in fibrodysplasia ossificans progressiva, as well as Phase II combination data among patients with obesity.
Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.
AstraZeneca’s IL-5 blocker has again missed in COPD, adding to a number of disappointments for biologics in this disease. Complex biology and overlapping inflammatory pathways seem to be at the heart of the problem.
The company’s cardiometabolic leader Ken Custer discusses the topline ACHIEVE-3 results in diabetes and just-published full results of ATTAIN-1 in obesity of orforglipron, with a pledge to maximize access to the oral GLP-1 therapy worldwide, once approved.
The dual TNFα/OX40L drug comfortably beat placebo in reducing symptoms of hidradenitis suppurativa but no news on Phase III plans yet.
The company announced positive topline Phase III results for the first of a series of Phase III studies of the drug in inadequately controlled disease.
The company reported that the Phase III EFZO-FIT trial in pulmonary sarcoidosis did not meet the primary endpoint, but showed improvement on a secondary endpoint.
A pause to Lilly’s plans for a UK biotech incubator reflect escalating tensions between pharma and the British government.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
With data generated from China-only trials and consistency issues lingering, Chinese drug makers presented impressive results from early-stage studies of their assets at the World Conference on Lung Cancer annual conference.
The company announced positive monotherapy and chemotherapy-combination data for the RAS(ON) inhibitor in first-line pancreatic ductal adenocarcinoma.
The EMA is reviewing the IL-23-targeting oral peptide which the company claims will transform the plaque psoriasis treatment paradigm.
Indian firms are upping indigenization, exploring AI application and expanding use of technology platforms like self-amplifying mRNA to develop vaccines against age-agnostic diseases like malaria, dengue, flu and Nipah encephalitis
The privately owned biotech said it would pause its Phase I/II study of CAP-002 in STXBP1-related disorders after the first patient in the study died.
PMV announced positive data from its Phase II trial in multiple TP53 Y220C-mutant solid tumors, with the second-line ovarian cancer opportunity worth up to $630m.
Interim Phase II data showed a 76% response rate with pumitamig plus chemo in first-line extensive-stage small-cell lung cancer, largely in line with data from an earlier China-only trial. Analysts say more mature outcomes data will be key as a Phase III trial advances.
Regeneron’s CEO has highlighted the large market potential for effective new anti-allergy treatments after the company reported positive data from a pair of allergen-blocking antibodies.
The companies’ multi-billion dollar collaboration on antibody-drug conjugates could be starting to pay off, with a potential first-in-class filing for ifinatamab deruxtecan (I-Dxd) based on promising Phase II data just presented at WCLC.